FTRE · Fortrea Holdings Inc.
$19.95
+0.21 (+1.06%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$1.89B
Shares
95.10M
Volume · Sep 30
1.48M
Avg daily vol (3M)
1.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.95
Open$19.41
Day$19.39–20.02
52W close$8.42–20.70
Avg vol 30d1.3M
Short int12.6M · 13.2% float · 10.2d
Short vol71%
Last earningsJul 29, 2026
DataJun 2023–Sep 2026
Filing10-Q · Jul 29
Up next
Next earnings call
Oct 25, 2026
Est · unconfirmed
· in 3 wks
filed Jul 29, 2026
call held Jul 29, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.68B
Trailing 12 months
Net income (TTM)
−$85.20M
Trailing 12 months
Revenue growth YoY
-4.5%
Year over year
Operating margin
-0.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
10.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$885.70M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.6%
Year over year · more shares
Price change (1Y)
+135.0%
Trailing year
Short interest
13.2%
Latest settlement · 10.2 days to cover
AI Brief
Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26
TL;DR. Fortrea reported Q2 2026 revenue of $678.2 million (down 4.5% YoY) and adjusted EBITDA of $58.7 million (up from $54.9M), raised full-year 2026 guidance, and booked $720.4M in net new business with a 1.06x book-to-bill, but its newly appointed CFO was placed on leave amid litigation tied to his prior employer, prompting an interim CFO appointment.
Bullish
- + Raised full-year 2026 revenue guidance to $2.62B-$2.69B and adjusted EBITDA to $205M-$220M.
- + Q2 book-to-bill of 1.06x with fourth consecutive quarter above 1.0x and trailing 12-month of 1.12x; first-half net new business awards up 19% YoY.
- + Q2 adjusted EBITDA grew to $58.7M from $54.9M on cost savings and operational efficiencies.
- + Operating cash flow improved to $28.9M (from $21.8M) and free cash flow to $19.9M (from $14.3M), with no revolver borrowings.
Bearish
- − Q2 revenue declined 4.5% YoY to $678.2M due to lower pass-throughs and FSP headwinds.
- − Newly appointed CFO Jason Knoblauch placed on paid leave after a Delaware court granted a TRO tied to alleged restrictive covenant violations by his prior employer.
- − Q2 GAAP net loss of $(13.2)M with $(0.14) diluted loss per share.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
+6%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
94%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
+113%
trailing
YTD return
+16%
this year
Relative strength
+101%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +45 funds added
Insider flow
Distributing
Net -$4.3M over 90 days · 100% sells
Short interest
Rising
13.20% of float · ▲ +5.1% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
338 holders — mid 3-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
−195%
Y/Y
Balance sheet
$878.2M
net debt
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Revenues
· full-year 2026
Initiated
$2.62B – $2.69B
prior FY $2.72B
midpoint −2.5% Y/Y
Adjusted EBITDA
· full-year 2026
Non-GAAP
Initiated
$205M – $220M
Guided vs delivered
· last 2 settled
Revenue guidance
full year 2024
guided $2.7B – $2.75B
$2.7B
Miss −1.0%
Revenues
full year 2023
guided $3.08B – $3.13B
$2.84B
Miss −8.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
94%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +45 funds added
Insider flow
Distributing
Net -$4.3M over 90 days · 100% sells
Short interest
Rising
13.20% of float · ▲ +5.1% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
338 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $8
Now $20 · 94%
Range high $21
vs 200-day avg +32%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FTRE
this stock
Fortrea Holdings Inc.
|
$1.89B | +15.7% | +1.0% | — | 13.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FTRE | +2.2% | +12.6% | +112.7% | +8.6% | +15.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +2.9% | +12.5% | +100.5% | +9.2% | +3.8% |